Evidence based pathology: Are EGFR tests valid predictors of treatment response to erlotinib or gefitinib in patients with pulmonary adenocarcinoma?

被引：0
|
作者：
Dastane, A. M. [1 ]
Gupta, R. [1 ]
Mckenna, R. J. [1 ]
Marchevsky, A. [1 ]
机构：
[1] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
来源：
LABORATORY INVESTIGATION | 2008年 / 88卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
1548
引用
收藏
页码：340A / 340A
页数：1
相关论文
共 50 条
  • [41] Evidence-based guidelines for the utilization of immunostains in diagnostic pathology: Pulmonary adenocarcinoma versus mesothelioma
    Marchevsky, Alberto M.
    Wick, Mark R.
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2007, 15 (02): : 140 - 144
  • [42] Trichomegaly and scalp hair changes following treatment with erlotinib in pulmonary adenocarcinoma patients: A case report and literature review
    Zheng, Hua
    Zhang, Hongmei
    Zhang, Tongmei
    Wang, Qunhui
    Hu, Fanbin
    Li, Baolan
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2016, 12 (03) : 1287 - 1292
  • [43] PREDICTORS OF RESPONSE TO ANTIBIOTIC TREATMENT OF PULMONARY EXACERBATIONS IN CYSTIC FIBROSIS PATIENTS
    Ratjen, F.
    Stanojevic, S.
    Sonneveld, N.
    Grasemann, H.
    Yau, Y.
    Tullis, E.
    Wilcox, P. G.
    Freitag, A.
    Chilvers, M.
    Waters, V. J.
    PEDIATRIC PULMONOLOGY, 2014, 49 : 355 - 355
  • [44] Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF)
    Balestro, Elisabetta
    Turato, Graziella
    Biondini, Davide
    Pavanello, Sofia
    Fraccaro, Alessia
    Rigobello, Chiara
    Bazzan, Erica
    Campisi, Manuela
    Baraldo, Simonetta
    Cosio, Manuel
    Saetta, Marina
    Spagnolo, Paolo
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [45] SIMILAR EFFICACY OF EGFR TYROSINE KINASE INHIBITORS REGARDLESS OF TREATMENT SEQUENCE FOR THE PATIENTS WITH EGFR MUTATION-POSITIVE PULMONARY ADENOCARCINOMA
    Koo, Dong Hoe
    Kim, Kyu-Pyo
    Choi, Chang-Min
    Lee, Dae-Ho
    Lee, Jae Cheol
    Lee, Jung-Shin
    Jang, Se Jin
    Kim, Sang-We
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S409 - S410
  • [46] Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany
    Katharina Schremser
    Wolf H. Rogowski
    Sigrid Adler-Reichel
    Amanda L. H. Tufman
    Rudolf M. Huber
    Björn Stollenwerk
    PharmacoEconomics, 2015, 33 : 1215 - 1228
  • [47] Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany
    Schremser, Katharina
    Rogowski, Wolf H.
    Adler-Reichel, Sigrid
    Tufman, Amanda L. H.
    Huber, Rudolf M.
    Stollenwerk, Bjoern
    PHARMACOECONOMICS, 2015, 33 (11) : 1215 - 1228
  • [48] FIRST-LINE GEFITINIB, ERLOTINIB, AND AFATINIB PROVIDED SIMILAR CLINICAL EFFICACY IN PATIENTS WHO HAD STAGE IV LUNG ADENOCARCINOMA HARBORING RARE EGFR MUTATION IN TAIWAN
    Yang, Chih Jen
    Tsai, Ming-Ju
    Hung, Jen-Yu
    Lee, Mei-Hsuan
    Huang, Ming-Shyan
    Chong, Inn-Wen
    RESPIROLOGY, 2018, 23 : 293 - 293
  • [49] Combination of chemotherapy and gefitinib as first-line treatment of patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomised controlled trial
    Han, B.
    Jin, B.
    Zhang, Y.
    Chu, T.
    Gu, A.
    Xu, J.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S113 - S114
  • [50] Predictors of Pulmonary Function Response to Treatment with Salmeterol/fluticasone in Patients with Chronic Obstructive Pulmonary Disease
    Lee, Jae Seung
    Huh, Jin Won
    Chae, Eun Jin
    Seo, Joon Beom
    Ra, Seung Won
    Lee, Ji-Hyun
    Kim, Eun-Kyung
    Lee, Young Kyung
    Kim, Tae-Hyung
    Kim, Woo Jin
    Lee, Jin Hwa
    Lee, Sang-Min
    Lee, Sangyeub
    Lim, Seong Yong
    Shin, Tae Rim
    Yoon, Ho Il
    Sheen, Seung Soo
    Oh, Yeon-Mok
    Lee, Sang-Do
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2011, 26 (03) : 379 - 385
12345